valopicitabine and HIV-Infections

valopicitabine has been researched along with HIV-Infections* in 2 studies

Reviews

2 review(s) available for valopicitabine and HIV-Infections

ArticleYear
Emerging therapies for hepatitis C and HIV in drug abusers: drugs and strategies.
    Journal of addictive diseases, 2008, Volume: 27, Issue:2

    New drug therapies to treat hepatitis C (HCV) and HIV infection are being developed with improved understanding of the molecular structures of the viruses themselves, the pathogenesis of infection and the specific immune responses needed to eradicate or control these infections. Interferon and ribavirin based therapies will continue to be a component of HCV therapy for the near future combined with other novel compounds directed at targets of viral replication, immunomodulation or cell entry. The goals of anti-HCV therapy are viral eradication for differing genotypes and prevention of hepatic morbidity such as hepatocellular carcinoma and cirrhosis. Future antiretroviral therapies for HIV will include agents that focus on new classes of inhibitors of viral replication and cell binding. The new treatment choices in HIV will need to ensure effective and durable viral suppression especially against highly resistant virus strains, regimen tolerability and improved toxicity.

    Topics: Anti-Retroviral Agents; Antiviral Agents; Comorbidity; Hepatitis C, Chronic; HIV Infections; Humans; Pyrimidine Nucleosides; Pyrrolidinones; Quinolones; Raltegravir Potassium; Substance Abuse, Intravenous

2008
Hepatitis C protease and polymerase inhibitors in development.
    AIDS patient care and STDs, 2008, Volume: 22, Issue:6

    Hepatitis C infection (HCV) remains a global problem and the current anti-HCV therapies available in the clinic have sustained virologic response rates (SVR) of only about 50%, especially in HCV genotype 1-infected subjects. The SVR is even lower in HIV-HCV co-infected patients, estimated at only about 30-40%. However, exciting new research is under way to find new anti-HCV therapies. Presently, efforts to develop new anti-HCV agents for HCV-infected persons who fail pegylated interferon and ribavirin-based therapies have focused on inhibitors of key HCV enzymes such as the HCV NS3 protease and the NS5B polymerase. There are two protease inhibitors, telaprevir (VX-950, Vertex) and boceprevir (SCH 503034, Schering-Plough); and three polymerase inhibitors, valopicitabine (NM283, Idenix), R1626 (Roche), and HCV-796 (Viropharma) that have advanced to late-stage clinical trials. Of these aforementioned agents, telaprevir is the most advanced in clinical development. Early trial results on efficacy, safety, and HCV drug-resistance profiles of these novel agents will be discussed in this review paper.

    Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Multicenter Studies as Topic; Oligopeptides; Proline; Protease Inhibitors; Pyrimidine Nucleosides; Randomized Controlled Trials as Topic

2008